- Community-Beiträge
- Aktuellste Threads
Welche Unternehmen überraschen positiv und welche enttäuschen? Jetzt lesen!
| Umsatz in Mio. | 35,00 $ |
| Operatives Ergebnis (EBIT) in Mio. | 1,58 $ |
| Jahresüberschuss in Mio. | 1,49 $ |
| Umsatz je Aktie | 5,31 $ |
| Gewinn je Aktie | 0,23 $ |
| Gewinnrendite | +0,04% |
| Umsatzrendite | - |
| Return on Investment | +1,62% |
| Marktkapitalisierung in Mio. | 26,39 $ |
| KGV (Kurs/Gewinn) | 17,39 |
| KBV (Kurs/Buchwert) | - |
| KUV (Kurs/Umsatz) | 16,74 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | - |
| Streubesitz | 2,05% |
| Aktientyp | Stammaktie |
| +4,18% | Orbimed Advisors, LLC |
| +3,10% | RA Capital Management, LLC |
| +2,38% | COMMODORE CAPITAL LP |
| +0,89% | HHG PLC |
| +0,83% | Woodline Partners LP |
| +0,60% | Fairmount Funds Management LLC |
| +0,42% | Vanguard Group Inc |
| +0,20% | Renaissance Technologies Corp |
| +0,20% | JBF Capital, Inc. |
| +0,11% | BlackRock Inc |
| +0,10% | Geode Capital Management, LLC |
| +0,10% | Jefferies Group Inc |
| +0,10% | Bridgeway Capital Management, LLC |
| +0,09% | Citadel Advisors Llc |
| +0,09% | Group One Trading, LP |
| +0,06% | Morgan Stanley - Brokerage Accounts |
| +0,05% | Bank of New York Mellon Corp |
| +0,04% | Longwood Capital Partners LLC |
| +0,04% | Marquette Asset Management Inc. |
| +0,04% | State Street Corporation |
| +84,35% | Weitere |
| +2,05% | Streubesitz |
Zahlen für 2021
"The Company currently expects that its full-year 2022 research and development expenses will range between $60 million and $65 million and that its full-year 2022 general and administrative expenses will range between $13 million and $15 million. The Company expects that its cash, cash equivalents and investments as of December 31, 2021, will be sufficient to enable it to fund its planned operations substantially through the first quarter of 2023."
https://ir.imaratx.com/news-releases/news-release-details/imara-reports-full-year-2021-financial-results-and-business
Die Pipeline sieht ziemlich dünn aus:
-Added clinical indication for tovinontrine to include the treatment of HFpEF;
anticipate first subject dosing in Phase 2 trial in second quarter of 2022
- Expanded pipeline with addition of IMR-261, an oral, clinic-ready Nrf2 activator
with potential indications in hemoglobin and iron overload disorders
Weiterentwicklung von IMR-687 wird nicht fortgesetzt
https://www.fiercebiotech.com/biotech/imara-flunks-phase-2b-trials-sickle-cell-and-thalassemia-wiping-out-clinical-pipeline
Zahlen für Q3/21
https://ir.imaratx.com/news-releases/news-release-details/imara-reports-third-quarter-2021-financial-results-and-business
zuletzt zwei Insider-Käufe:
https://www.gurufocus.com/stock/IMRA/insider?search=imara
